Clinical oncology (Royal College of Radiologists (Great Britain)) · 2026
Multidisciplinary Tumor Board in Oropharyngeal Cancer: Impact on Treatment Regimen, Treatment Initiation and Survival.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Burkhardt V, El-Shabrawi K, Spörlein A, Schulz T, Riemann S, Becker C, Yildiz C
Аннотация
AIMS: This study was carried out to assess the impact of a pretherapeutic multidisciplinary tumor board (MTB) presentation in a multidisciplinary team (MDT) on patient's outcomes and treatment in oropharyngeal cancer (OPC).
MATERIALS AND METHODS: In this retrospective single-center study, 572 patients diagnosed with OPC and treated between 2010 and 2020 were included. The cohort was split into two groups: patients with and without pretherapeutic MTB presentation. Data on patient demographics, tumor characteristics, treatment, and the time to treatment initiation (TTI) were collected retrospectively.
RESULTS: Primary findings revealed no difference in 5-year survival (5-YS) and 5-year disease-free survival (5-YDFS) for both groups (P ≥ .05). Subgroup analysis for UICC (Union for International Cancer Control) stages I-IV did not show a significant improvement in 5-YS either (all P > .05). TTI differed significantly between both groups, with a mean of 36.8 days (Confidence interval[CI]: 34.2;39.4) in the MTB group compared to 25.9 days (CI: 18.4;33.3) in the non-MTB group (P < .001). Furthermore, patients presented at the MTB did receive primary chemo/radiotherapy more frequently than those who were treated without pretherapeutic MTB presentation (31.9% vs 59.4%, P < .001).
CONCLUSION: The findings show both beneficial and negative effects of MTB presentation in individuals with OPC. More multicenter studies will be needed to determine the effect of TTI and the therapeutic regimen on the survival of OPC patients.
MATERIALS AND METHODS: In this retrospective single-center study, 572 patients diagnosed with OPC and treated between 2010 and 2020 were included. The cohort was split into two groups: patients with and without pretherapeutic MTB presentation. Data on patient demographics, tumor characteristics, treatment, and the time to treatment initiation (TTI) were collected retrospectively.
RESULTS: Primary findings revealed no difference in 5-year survival (5-YS) and 5-year disease-free survival (5-YDFS) for both groups (P ≥ .05). Subgroup analysis for UICC (Union for International Cancer Control) stages I-IV did not show a significant improvement in 5-YS either (all P > .05). TTI differed significantly between both groups, with a mean of 36.8 days (Confidence interval[CI]: 34.2;39.4) in the MTB group compared to 25.9 days (CI: 18.4;33.3) in the non-MTB group (P < .001). Furthermore, patients presented at the MTB did receive primary chemo/radiotherapy more frequently than those who were treated without pretherapeutic MTB presentation (31.9% vs 59.4%, P < .001).
CONCLUSION: The findings show both beneficial and negative effects of MTB presentation in individuals with OPC. More multicenter studies will be needed to determine the effect of TTI and the therapeutic regimen on the survival of OPC patients.